← Latest news 
AstraZeneca India eyes Rs 3400 crore sale of 64 acre Bengaluru land as developers circle
Business
Published on 24 April 2026
Multiple pharma and real estate players want in
AstraZeneca Pharma India is planning to sell a 64-acre site in Bengaluru, targeting about ₹3,400 crore as part of its land monetisation strategy. The parcel has attracted interest from developers including the Sattva Group, Aurobindo Pharma and RMZ, with negotiations expected to shape how quickly the company can unlock value from the asset.
- AstraZeneca India plans to sell a 64-acre Bengaluru land parcel
- The expected value is around ₹3,400 crore
- Developers and pharma-linked players including Sattva, Aurobindo and RMZ are interested
- The move fits the company’s broader land monetisation strategy
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times